ReviewInternational journal of oncology2026
Targeted therapy in BRAF‑mutant melanoma: Advances and challenges (Review).
Review in International journal of oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over half of patients with melanoma exhibit v‑Raf murine sarcoma viral oncogene homolog B (BRAF) mutations, which drive hyperactivation of the MAPK pathway and confer high proliferative potential. To target this oncogenic mutation, BRAF inhibitors, as well as MEK inhibitors (targeting the downstream effector of BRAF), have been approved for melanoma therapy. Although these inhibitors initially decrease the tumor burden, nearly all patients eventually develop drug resistance, leading to aggressive disease relapse at both the primary and metastatic sites. Understanding the mechanisms underlying tumor escape from drug lethality is crucial for the development of strategies against melanoma. The present study aimed to summarize the discovery, development and clinical evolution of the BRAF and MEK inhibitors approved for the treatment of melanoma, their notable efficacy in suppressing aggressive melanoma progression and the underlying mechanisms of acquired resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.